Table 2 Dynamic of basic clinical and laboratory parameters among children with JIA starting treatment with etanercept (N = 197) at baseline and at the final measurement during 1 year follow-up
Characteristics | Baseline, median (IQR) | 1 year follow-up, median (IQR) |
|---|---|---|
Active joint count | 4 (2-10) | 0 (0-3) |
Persistent oligoarticular | 2 (2-4) | 0 (0-0) |
Extended oligoarticular | 6 (5-10) | 0 (0-0) |
Polyarticular RF- | 14 (6-23.5) | 0 (0-2) |
Enthesitis-related | 5 (2.5-9) | 0 (0-1.5) |
Limited joint count | 4 (2-11) | 0 (0-2) |
Persistent oligoarticular | 2 (2-3.5) | 0 (0-0) |
Extended oligoarticular | 6 (3-10) | 0 (0-1) |
Polyarticular RF- | 15 (6.5-25.5) | 0 (0-6) |
Enthesitis-related | 4.5 (4-9) | 0 (0-1.5) |
Swollen joint count | 4 (2-8) | 0 (0-0) |
Persistent oligoarticular | 2 (2-4) | 0 (0-0) |
Extended oligoarticular | 6 (4-6) | 0 (0-0) |
Polyarticular RF- | 9 (5-12.5) | 0 (0-2) |
Enthesitis-related | 4 (2-7) | 0 (0-0) |
Pained joint count | 4 (2-10) | 0 (0-0) |
Persistent oligoarticular | 2 (1.5-3) | 0 (0-0) |
Extended oligoarticular | 6 (3-9) | 0 (0-0) |
Polyarticular RF- | 12 (4-23) | 0 (0-0) |
Enthesitis-related | 4.5 (3-9) | 0 (0-1) |
Morning stiffness, min | 30 (0-60) | 0 (0-15) |
Persistent oligoarticular | 30 (0-60) | 0 (0-0) |
Extended oligoarticular | 35 (0-60) | 0 (0-3) |
Polyarticular RF- | 60 (20-120) | 0 (0-0) |
Enthesitis-related | 60 (15-120) | 0 (0-1) |
Physician global of disease (0-100 mm) | 60 (45-80) | 5 (0-15) |
Persistent oligoarticular | 50 (42-70) | 0 (0-4) |
Extended oligoarticular | 65 (46-80) | 3 (0-14) |
Polyarticular RF- | 70 (56-86) | 6 (2-19) |
Enthesitis-related | 68.5 (54.5-82.5) | 4.5 (0.5-11) |
Parent/patient global of well-being (0-100 mm) | 68 (50-82.5) | 6.5 (2.8-14.3) |
Persistent oligoarticular | 60 (49-70) | 2 (0-7) |
Extended oligoarticular | 68 (50-81) | 5 (3-10) |
Polyarticular RF- | 73.5 (60-87) | 9 (2-15.5) |
Enthesitis-related | 70 (50-90) | 4.5 (0-12) |
Childhood health assessment questionnaire (0-3) | 1.3 (0.5-1.9) | 0 (0-0.2) |
Persistent oligoarticular | 0.78 (0.5-1.5) | 0 (0-0) |
Extended oligoarticular | 1.5 (1-1.9) | 0 (0-0.25) |
Polyarticular RF- | 1.75 (13-2.25) | 0 (0-0.75) |
Enthesitis-related | 1.5 (0.75-2.5) | 0 (0-0.25) |
Juvenile arthritis disease activity score-71 | 19.2 (13.8-28.5) | 1.1 (0.3-3.9) |
Persistent oligoarticular | 14.9 (11.7-18.9) | 0.5 (0-1.1) |
Extended oligoarticular | 21.8 (16.3-28.5) | 1 (0-2.5) |
Polyarticular RF- | 29.6 (20.6-39.8) | 1.45 (0.65-6.4) |
Enthesitis-related | 20.6 (15.6-30.7) | 1.1 (0.1-3.6) |
Erythrocyte sedimentation rate, mm/h | 21 (12-35) | 5 (3-11) |
Persistent oligoarticular | 19.5 (10-28) | 5 (2-7) |
Extended oligoarticular | 20 (15-35) | 4 (2-12) |
Polyarticular RF- | 25.5 (16-41.5) | 5 (3-15.5) |
Enthesitis-related | 30 (8.5-59.5) | 5 (4-13.5) |
C-reactive protein, mg/l | 6.6 (1.9-19.7) | 1 (0-4.6) |
Persistent oligoarticular | 2.6 (1-10) | 0 (0-1) |
Extended oligoarticular | 6.4 (2.4-15) | 1 (0-3) |
Polyarticular RF- | 9.8 (4-27) | 1 (0-6.5) |
Enthesitis-related | 16.7 (7.6-52.3) | 3.7 (0.9-12.6) |